# David Cook

> David N. Cook, Ph.D., is the founder and CEO of Edgewood Oncology, a Boston-based virtual biotech advancing BTX-A51, a first-in-class small molecule that hits three master regulators of cancer at once (CK1 alpha, CDK7 and CDK9) to switch on programmed cell death. A chemist by training, with an A.B. from Harvard and a Ph.D. from UC Berkeley, Cook has spent roughly 30 years building venture-backed life sciences companies, helping raise more than $1 billion, leading three IPOs, orchestrating two acquisitions, and contributing to five commercialized products. He emerged Edgewood from stealth in March 2024 with a $20 million Series A led by Alta Partners.

- **Role:** Founder & CEO at Edgewood Oncology
- **Organizations:** Edgewood Oncology, Thetis Pharmaceuticals (Board of Managers), Forma Therapeutics, Seres Therapeutics, Anza Therapeutics, Eligix, Cerus Corporation
- **Nationality:** American
- **Education:** A.B., Chemistry, Harvard University, Ph.D., Chemistry, University of California, Berkeley
- **Known for:** Founded and leads Edgewood Oncology as CEO, Helped raise more than $1 billion across his career, Led three successful IPOs

## Career timeline

- **2020** — Appointed Chief Scientific Officer at Forma Therapeutics
- **2023** — Edgewood Oncology licenses BTX-A51 from Yissum (Hebrew University of Jerusalem)
- **2024** — Emerges Edgewood Oncology from stealth with $20M Series A led by Alta Partners
- **2025** — First patient dosed in Phase 1 investigator-sponsored liposarcoma study; new preclinical data presented at AACR 2025
- **2025** — Appointed to the Board of Managers at Thetis Pharmaceuticals

## Achievements

- Founded and leads Edgewood Oncology as CEO
- Helped raise more than $1 billion across his career
- Led three successful IPOs
- Orchestrated two corporate acquisitions
- Contributed to the development and commercialization of five licensed products
- Closed a $20 million Series A led by Alta Partners in March 2024
- Contributed to a late-stage clinical program for sickle cell disease

## Latest updates

- **2025-10** — Appointed to the Board of Managers at Thetis Pharmaceuticals.
- **2025-04** — Edgewood dosed its first patient in a Phase 1 investigator-sponsored liposarcoma study and presented new preclinical data at AACR 2025.
- **2024-03** — Edgewood Oncology emerged from stealth with a $20M Series A led by Alta Partners.

## Links

- Website: https://edgewoodoncology.com
- LinkedIn: http://www.linkedin.com/in/davidncook

---

Profile page: https://yespress.io/david-cook
Published by YesPress — https://yespress.io
Last updated: 2026-06-13